Roche lung cancer drug bags another ‘breakthrough’ at the FDA – FierceBiotech

by lowes1 on September 23, 2013

Roche lung cancer drug bags another 'breakthrough' at the FDA
FierceBiotech
Roche has won bragging rights to the FDA's new Breakthrough Therapy designation for its ALK inhibitor alectinib, a non-small cell lung cancer drug which will be featured at an upcoming presentation at the European Cancer Congress in Amsterdam at the 
ROCHE HOLDING LTD. (BEARER SHARE) : Roche to share important oncology 4-traders (press release)

all 2 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: